Adult Hippocampal Neurogenesis and mRNA Expression are Altered by Perinatal Arsenic Exposure in Mice and Restored by Brief Exposure to Enrichment

Christina R. Tyler, Andrea M. Allan*
Department of Neuroscience, University of New Mexico School of Medicine, Albuquerque, New Mexico, United States of America

Abstract

Arsenic is a common and pervasive environmental contaminant found in drinking water in varying concentrations depending on region. Exposure to arsenic induces behavioral and cognitive deficits in both human populations and in rodent models. The Environmental Protection Agency (EPA) standard for the allotment of arsenic in drinking water is in the parts-per-billion range, yet our lab has shown that 50 ppb arsenic exposure during development can have far-reaching consequences into adulthood, including deficits in learning and memory, which have been linked to altered adult neurogenesis. Given that the morphological impact of developmental arsenic exposure on the hippocampus is unknown, we sought to evaluate proliferation and differentiation of adult neural progenitor cells in the dentate gyrus after 50 ppb arsenic exposure throughout the perinatal period of development in mice (equivalent to all three trimesters in humans) using a BrdU pulse-chase assay. Proliferation of the neural progenitor population was decreased by 13% in arsenic-exposed mice, but was not significant. However, the number of differentiated cells was significantly decreased by 41% in arsenic-exposed mice compared to controls. Brief, daily exposure to environmental enrichment significantly increased proliferation and differentiation in both control and arsenic-exposed animals. Expression levels of 31% of neurogenesis-related genes including those involved in Alzheimer’s disease, apoptosis, axonogenesis, growth, Notch signaling, and transcription factors were altered after arsenic exposure and restored after enrichment. Using a concentration previously considered safe by the EPA, perinatal arsenic exposure altered hippocampal morphology and gene expression, but did not inhibit the cellular neurogenic response to enrichment. It is possible that behavioral deficits observed during adulthood in animals exposed to arsenic during development derive from the lack of differentiated neural progenitor cells necessary for hippocampal-dependent learning. This study is the first to determine the impact of arsenic exposure during development on adult hippocampal neurogenesis and related gene expression.

Introduction

Arsenic is a naturally occurring essential trace element found in soil deposits and water. Both natural and human sources contribute to the ubiquitous presence of arsenic in the environment; as such, several millions of people are exposed to this toxic metalloid in varying concentrations depending on location. Consistent exposure to arsenic results in a myriad of problems associated with almost every organ system in the body, including problems with renal, cardiovascular, reproductive, hepatic, and neurological systems [1]. It’s well established that arsenic is a toxin in high doses and a co-carcinogen in moderate doses; the last decade of research has shown arsenic to be a neurotoxin in low doses. The current EPA standard for arsenic in water is 10 parts per billion; however, many people in rural areas and developing countries, where arsenic is not regulated, are exposed to much higher levels of arsenic in their water. Developmental and continuous arsenic exposure induces significant deficits in long-term memory in children, as measured by the Wechsler Intelligence Scale for Children (WISC) [2]. Other research has revealed considerable deficits in learning and memory after several methods of arsenic exposure in both rodent models and in humans [2–9]. Additionally, developmental arsenic exposure alters cerebellar morphology in the brain and disrupts cell cycle dynamics of neuroepithelial cells in vivo [10,11]. Recently, we have demonstrated that developmental exposure to arsenic alters components of the hypothalamus-pituitary-adrenal (HPA) axis [12] including increased hypothalamic corticotrophin releasing hormone (CRH), altered corticosterone (CORT) secretion (both at baseline and in response to a stressor), decreased hippocampal 11β-HSD 1, and altered subcellular glucocorticoid receptor (GR) distribution in the hypothalamus. We have also reported deficits in learning tasks, including 8-way radial arm, novel object exploration, learned helplessness, and forced swim tasks, some of which are hippocampal-dependent [8,13]. The underlying mechanism responsible for these behavioral outcomes in adulthood after developmental exposure to arsenic has not been elucidated to date.

Of the two neurogenic regions of the brain capable of continual mitosis, adult neurogenesis in the dentate gyrus of the hippocampus has been implicated as an integral component of hippocam-
Adult neurogenesis involves proliferation of a neural progenitor cell (NPC) population comprised of neural stem cells left over from development and transient amplifying cells, differentiation of daughter cells from NPC into either glia or neurons, and survival and integration of these new cells into the hippocampal circuitry. Research conducted over the last decade has shown that ablation of adult neurogenesis in the hippocampus results in substantial deficits in learning and memory and that these new neurons are required for integration of new memories [17,18]. This budding population of cells seems particularly sensitive to environmental factors, as evidenced by decreased adult neurogenesis after exposure of several different neurotoxins, including adult or fetal exposure to alcohol [19–21] or nicotine [22,23], and fetal exposure to lead [24–26] or methylmercury [27,28]. This sensitivity in the hippocampus coupled with the vulnerability of the brain during development may result in an environment that is susceptible to damage even with low concentrations of toxin. However, the neurogenic environment shows plasticity to extrinsic factors like antidepressants, exercise, novelty, and environmental enrichment with toys and social interaction, all of which increase adult neurogenesis and learning [29–31]. Environmental enrichment also enhances cognitive performance, decreases depression and anxiety, and increases proliferation and differentiation of adult neural progenitor cells [31–34].

Based on our previously published behavioral data and research supporting the link between learning and memory and adult neurogenesis, we hypothesized that our environmentally relevant perinatal arsenic exposure model induces deficits in proliferation and differentiation of neural progenitor cells in the dentate gyrus of exposed animals. This deficit may be responsible for the behavioral outcomes we observe in these animals [8,13]. We found that developmental exposure to a low concentration of arsenic (50 parts per billion, ppb) over the first three trimester equivalents significantly decreased the number of differentiated neural progenitor cells but did not affect proliferation of these cells in adult mice. Additionally, perinatal arsenic exposure altered 31% of target neurogenesis-related genes as well, Including several involved in growth and differentiation in adult animals. Brief exposure to an enriched environment increased both proliferation and differentiation of neural progenitor cells in both control and arsenic-exposed animals and significantly reversed mRNA expression of aberrantly expressed neurogenesis genes. Thus, it is possible that impaired hippocampal adult neurogenesis is a candidate mechanism by which developmental arsenic exposure induces deficits in learning and memory seen in adulthood.

**Methods**

*Note:* Arsenic is a known human carcinogen, and all arsenicals were handled with caution according to MSDS standards.

**Ethics Statement**

All experiments were performed in accordance with protocols approved by the University of New Mexico Institutional Animal Care and Use Committee (Protocol number: 11–100679 HSC).

**Perinatal Arsenic Exposure Paradigm**

The arsenic exposure paradigm was performed as previously described [13]. Briefly, C37BL/6j mice (Jackson Laboratories, Bar Harbor, ME) were bred and maintained in the University of New Mexico (UNM) Animal Research Facility on a 12-hour reverse light/dark cycle with lights off at 0800 hr. Animals had *ad libitum* access to food and water in a temperature controlled (22°C) room. Female mice were assigned to either control (arsenic-free) or arsenic exposure groups and acclimated for seven days prior to mating. Fifty parts per billion (ppb) arsenic-treated water was prepared from sodium arsenate (Sigma-Aldrich, St. Louis, MO) and ultra pure water from a Milli-Q Plus purification system (Millipore, Billerica, MA). Dams were provided *ad libitum* access to 50 ppb arsenic (equivalent to 50 μg/L) or normal tap water during breeding and pregnancy until pups were weaned at approximately PD23–25. After weaning, pups were group housed, four per cage, with *ad libitum* access to food and normal tap water (Figure 1). Male mice were used for all studies with only one animal from each litter to eliminate litter effects, *n* = 7–9 mice per group. The UNM Health Sciences Center Institutional Animal Care and Use Committee approved all the procedures described in these studies. As described in our previous papers, the arsenic concentrations were 56 ppb in the arsenic-treated water and 6 ppb in standard tap water [8,13].

Average daily water consumption is not significantly different between arsenic-exposed and control groups.

![Figure 1. Schematic of neurogenesis study in perinatally arsenic-exposed mice](image-url)

Female mice were given arsenic-treated water (50 ppb), made from sodium arsenate and ultra pure water, for seven days prior to mating. Dams drank arsenic-treated water (50 ppb) throughout pregnancy into the postnatal period. Offspring were weaned at PD23–25 and given tap water (~5 ppb As) in standard cages. Four i.p. BrdU injections (50 mg/kg) were given over the course of 12 hours on PD34; animals were sacrificed on PD35 and proliferation of adult neurogenesis was assessed. For assessment of differentiation, a subset of animals was sacrificed four weeks later on PD63. Another cohort of animals was used for the enriched environment experiments. Brief, daily (2–4 hours) exposure to an enriched environment with a ladder, toys, housing, a running wheel, and other animals began on PD35. For proliferation assessment, animals were sacrificed five days later on PD40; for differentiation assessment, animals were sacrificed at PD63 with exposure to enrichment lasting one month. Another cohort of animals with and without exposure to enrichment was sacrificed at PD70 for mRNA assessment of neurogenesis-related genes.

*doi:10.1371/journal.pone.0073720.g001*
We have previously assessed total arsenic concentration in whole brains of animals: perinatal arsenic exposure results in 2.24 ± 0.2 ppb arsenic in whole brains at PD35, which is significantly greater than 1.0 ± 0.24 ppb arsenic determined in age-matched control animals on tap water [8,13].

Enriched Environment Paradigm

For enrichment studies, PD35 male mice were separated into two groups: one with daily exposure to enrichment (enriched environment, EE) and one without exposure to enrichment (no enrichment, NE). Mice used for proliferation assessment were exposed to an enriched environment (EE) for 2–4 hours per day for five days after which proliferation was assessed at PD40 for both EE and NE groups. Mice used for differentiation assessment were exposed to an enriched environment for 2–4 hours per day for 28 days (approximately one month post last-BrdU injection) after which differentiation was assessed at PD63 for EE and NE groups. No enrichment control groups consisted of both perinatal arsenic-exposed animals and unexposed animals in which neither group had exposure to enrichment. The enriched environment consisted of toys (ladder, plastic house, chew toys) and a running wheel in a large housing container (48 cm × 27 cm × 20 cm). Toys were exchanged every other day, but the running wheel was kept throughout the exposure paradigm. The location of all the objects was changed every other day. All NE control groups (perinatal arsenic or control) and all enriched groups (perinatal arsenic or control) were maintained in standard housing (28 cm × 18 cm × 13 cm). Each standard housing cage contained two to three mice, while the enrichment cages contained four to six mice; the same four to six mice were exposed to enrichment together each day. All groups were given ad libitum access to food and tap water while in the enriched environment and in their own standard housing.

Histological Evaluation of Neurogenesis

To analyze adult neurogenesis, 5-bromo-2′-deoxyuridine (97% Sigma-Aldrich, St. Louis, MO) BrdU was used to label neural progenitor cells (NPC) in the dentate gyrus (DG) of the hippocampus of PD34 male mice for all groups. To reduce BrdU toxicity and double labeling of neural progenitor cells, a 12-hour, 4-injection paradigm was used with a low concentration of BrdU (50 mg/kg made in 0.9% sterile NaCl [35]). Assessment of proliferation or differentiation was performed either 12 hours (PD35) or 4 weeks (PD63) following the final BrdU injection, respectively. Brain slices were obtained according to an earlier published protocol [36]. Briefly, mice were euthanized with an i.p. injection of sodium pentobarbital followed by transcardiac perfusion with 4% PFA. Brains were dissected and post-fixed overnight in 4% PFA followed by equilibration in 30% sucrose for 48 hours. Brains were frozen in 30% sucrose and 40 μm coronal sections were obtained using a sliding microtome; tissue was stored at –20°C in 96-well plates with cryoprotectant (1:2:2 by volume glycerol, ethylene glycol, and 0.1 M PBS, pH 7.4). Immunohistochemical analysis for every 1-in-6 serial, floating, 40 μm section (240 μm apart) for the rostral-caudal extent of the hippocampus was performed. Free-floating sections were washed with 0.1 M TBS (0.15 M NaCl, 3 mM KCl, 30 mM Tris-base, pH 7.4) for 15 minutes. Sections were incubated for 30 minutes in 1 N HCl at 37°C, rinsed in 0.1 M borate buffer for 30 minutes, and rinsed several times in 0.1 M TBS. After one hour incubation in TBS-T (0.1 M TBS, 0.1% Triton X, and 3% normal goat serum), sections were obtained using a sliding microtome; tissue was stored at –20°C in 96-well plates with cryoprotectant (1:2:2 by volume glycerol, ethylene glycol, and 0.1 M PBS, pH 7.4). Immunohistochemical analysis for every 1-in-6 serial, floating, 40 μm section (240 μm apart) for the rostral-caudal extent of the hippocampus was performed. Free-floating sections were washed with 0.1 M TBS (0.15 M NaCl, 3 mM KCl, 30 mM Tris-base, pH 7.4) for 15 minutes. Sections were incubated for 30 minutes in 1 N HCl at 37°C, rinsed in 0.1 M borate buffer for 30 minutes, and rinsed several times in 0.1 M TBS. After one hour incubation in TBS-T (0.1 M TBS, 0.1% Triton X, and 3% normal goat serum), sections were incubated in primary antibodies BrdU (rat, 1:100, Abcam), Ki67 (mouse, 1:200, Vector), NeuN (mouse, 1:500, Millipore), doublecortin (rat, 1:500, Cell Signaling), and DAPI (1:1000, Oligo, Santa Cruz).

Figure 2. Perinatal arsenic exposure does not alter proliferation of NPC at PD35 in male mice. Representative images of neural progenitor cell (NPC) proliferation at PD35 in the dentate gyrus: (A) Colocalization of Ki67 (endogenous mitotic marker) and BrdU (exogenous S-phase marker) determine the proliferating pool of neural progenitor cells in (B) control and (C) arsenic-exposed animals. (D) There was no significant effect of treatment on the proliferation of neural progenitor cells, n = 7–9 mice per group (each from different litters). Results are expressed as the mean ± SEM. DAPI (blue), BrdU (green), Ki67 (red).

doi:10.1371/journal.pone.0073720.g002
Sigma) in TBS-T for 72 hours at 4°C. Sections were washed in 0.1 M TBS and incubated for one hour in appropriate fluorescent secondary antibodies (Alexa 488; Cy3; Cy5). Sections were mounted, coverslipped with DABCO, and maintained at 4°C in the dark until analysis; a minimum of n = 7 was analyzed for each group.

Figure 3. Perinatal arsenic exposure decreases NPC differentiation in PD63 male mice. (A) Colocalization of doublecortin (immature neuron marker DCX) or NeuN (mature neuron marker) and BrdU determine differentiated neurons derived from labeled neural progenitor cells. (B) Colocalization of BrdU with NeuN in the dentate gyrus reveals mature daughter cells of BrdU-labeled progenitor cells, (BrdU, green; DAPI, pink; NeuN blue). Arrows indicate colocalization of marks and cells that were counted. Representative images of neural progenitor differentiation at PD63 in the dentate gyrus of (C) control and (D) arsenic-exposed animals. (E) There was a significant effect of treatment on differentiation of neural progenitor cells; BrdU”DCX” and BrdU”NeuN” were significantly decreased after perinatal arsenic exposure, n = 7–9 mice per group (each from different litters). Results are expressed as the mean ± SEM. BrdU (green), DCX (red), NeuN (blue).

doi:10.1371/journal.pone.0073720.g003

Stereology
Stereoinvestigator software (Microbrightfield, Wiliston, VT) was used for assessment of adult neurogenesis. Both proliferation and differentiation were scored for at least 10, 1-in-6 serial sections throughout the rostral-caudal extent of the granule cell layer of the dentate gyrus for at least seven animals per group. BrdU with Ki67 positive cell counts were limited to the granule cell layer and subgranular zone next to the hilus; this was accomplished using...
StereoInvestigator to outline digital contours around each dentate gyrus for each section using a 10× objective. BrdU positive cells that were more than three nuclear diameters from the base of the granule cell layer or more than two nuclear diameters into the hilus were not counted, as only progenitor cells lie within this region. A two-micron guard zone was used with a 25 μm optical fractionator probe and a 40× objective for counting cells. As arsenic has been shown to induce DNA damage [37], proliferation was assessed via colocalization of BrdU positive cells (BrdU+Ki67+) with Ki67 positive (Ki67+) cells using unbiased stereology. Cells expressing only BrdU or only Ki67 were not counted; although, very few cells had BrdU+ labeling only. One month after the final BrdU injection, differentiation of progenitors was assessed via BrdU colocalized with either doublecortin (DCX) or BrdU colocalization with NeuN positive cells. Counts for both types of differentiated cells (immature DCX+ and mature NeuN+) were pooled together to determine the total impact of arsenic exposure on the differentiation capacity of NPC. Results are presented as cell counts directly from the StereoInvestigator analysis for the total number of cells throughout the entire dentate gyrus per animal. This assessment takes into account the section sampling fraction (SSF), the area subfraction (ASF), the thickness subfraction (TSF) and the total number of cells counted (Q): N = Q/(SSF×ASF×TSF). Phenotype analysis was performed for 100 randomly selected BrdU positive cells per animal for differentiation studies. Phenotypes were counted as BrdU+, BrdU+DCX+, or BrdU+NeuN+.

Confocal Microscopy
Images used for stereological analysis were collected using an Olympus DSU spinning disk confocal inverted IX-81 microscope endowed with argon and HeNe lasers. A Z-stack composite was obtained using a 40× objective throughout the orthogonal plane with appropriate filters for each secondary antibody for 10 slices per brain. A guard zone of 2 μm was used along with a probe of 25 μm. Cell bodies within the guard zone were not counted. Images for publication were acquired using a Zeiss LSM510 META confocal microscope endowed with a laser diode, one argon laser, and two HeNe lasers. Colocalization was visualized using a 63× oil objective (Figure 2A, 3A), while maximum

Figure 4. Brief, daily exposure to enrichment increases proliferation and differentiation in control and arsenic-exposed male mice. Representative images of increased (A) proliferation after brief exposure to enrichment for five days in arsenic-exposed animals at PD40 (BrdU (green), Ki67 (red), DAPI (blue)) and increased (B) differentiation after brief, daily exposure to enrichment for one month in arsenic-exposed animals at PD63 (BrdU (green), DCX (red), NeuN (blue)). (C) Perinatal arsenic exposure did not affect proliferation of NPC; exposure to enrichment for five days increased NPC proliferation at PD40 in both arsenic-exposed and control mice but was only significant in controls. (D) Perinatal arsenic exposure decreased the total number of differentiated cells (BrdU+DCX+ and BrdU+NeuN+); brief, daily exposure to enrichment for one-month increased differentiation in both arsenic-exposed and control animals at PD63, n=7–9 mice per group, each from different litters. (**p<.01, *p<.05).

doi:10.1371/journal.pone.0073720.g004
Table 1. Aberrant expression of neurogenesis-related genes in perinatal arsenic-exposed adult male mice compared to control age-matched animals.

| Accession Number | Gene Title          | Gene Symbol | Fold Regulation | p-value | Function                          |
|------------------|---------------------|-------------|----------------|---------|-----------------------------------|
| NM_009599        | Acetylcholinesterase| Ache        | 1.676          | <.01    | Apoptosis; Synaptogenesis         |
| NM_001008533     | Adenosine A1 receptor| Adora1      | 1.145          | <.05    | Apoptosis; GPCR Signaling         |
| NM_009685        | Amyloid beta (A4) precursor protein-binding, family B, member 1| Apbb1   | 3.042          | <.01    | Apoptosis; Axonogenesis           |
| NM_009696        | Apolipoprotein E    | Apoe        | 1.979          | <.01    | Synaptic Transmission             |
| NM_008553        | Achaete-scute complex homolog 1| Ascl1 | −1.374         | <.01    | Notch Signaling                   |
| NM_203491        | Cholinergic receptor, muscarinic 2, cardiac| Chrm2   | −2.024         | <.05    | GPCR Signaling; Synaptic Transmission |
| NM_133828        | CAMP responsive element binding protein 1| Creb1 | −1.468         | <.01    | Synaptic Transmission; Transcription Factor |
| NM_010025        | Doublecortin        | Dcx         | −2.030         | <.05    | Axonogenesis                       |
| NM_007865        | Delta-like 1        | Dll1        | 2.337          | <.05    | Notch Signaling; Cell Adhesion    |
| NM_010077        | Dopamine receptor D2| Drd2        | 1.649          | <.05    | Axonogenesis; GPCR Signaling; Synaptic Transmission |
| NM_010110        | Ephrin B1           | Efnb1       | 1.279          | <.05    | Cell Adhesion                     |
| NM_008006        | Fibroblast growth factor 2| Fgf2      | −1.371         | <.01    | Growth Factor; Synaptic Transmission |
| NM_010227        | Filamin, alpha      | Flna        | 1.748          | <.01    | Transcription Factor              |
| NM_013904        | Hairy/enhancer-of-split related with YRPW motif 2| Hey2   | −1.536         | <.05    | Notch Signaling; Transcription Factor |
| NM_001039934     | Microtubule-associated protein 2| Mtap2   | −1.870         | <.01    | Axonogenesis                       |
| NM_010883        | Norrie disease (pseudoglioma)| Ndp    | 1.312          | <.01    | Growth Factor; WNT Signaling      |
| NM_010897        | Neurofibromatosis 1 | Nf1         | −1.666         | <.05    | Synaptic Transcription            |
| NM_007871        | Noggin              | Nog         | 1.653          | <.05    | Axonogenesis                       |
| NM_178591        | Neuregulin 1        | Nrg1        | −1.608         | <.01    | Growth Factor; Notch Signaling    |
| NM_008744        | Netrin 1            | Ntn1        | 1.913          | <.05    | Apoptosis                         |
| NM_011855        | Odd Oz/ten-m homolog 1| Otd1     | −1.256         | <.05    | Growth Factor                     |
| NM_013627        | Paired box gene 6   | Pax6        | −1.390         | <.05    | Transcription Factor              |
| NM_008973        | Pleiotrophin        | Ptn         | −1.256         | <.05    | Cell Cycle; Cytokine; Growth Factor |
| NM_019413        | Roundabout homolog 1| Robo1       | −1.552         | <.01    | Cell Adhesion                     |
| NM_011577        | Transforming growth factor, beta 1| Tgfβ1  | −1.320         | <.05    | TGFβ Signaling; Cytokine          |
| NM_022312        | Tenascin R          | Tnr         | −1.338         | <.01    | Cell Adhesion                     |

Intensity projections of Z-stacks were acquired with a 20× objective.

Real-time PCR Analysis

The dentate gyrus of the hippocampus in PD70 male mice was isolated, microdissected as described by Hagihara and colleagues, snap frozen in liquid nitrogen, and stored at −80°C until use [38,39]. n = 6 litters/group, where one mouse is used per litter to eliminate litter effects. Total RNA was extracted from homogenized frozen tissue using the QiAshredder homogenizer (Qiagen, Valencia, CA) and the RNeasy Mini Kit (Qiagen, Valencia, CA). The concentration of mRNA was assessed using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE); the 260/280 absorbance ratio for all RNA was ~2.0. Isolated 750 ng mRNA was converted to cDNA using the RT2 First Strand Kit (SABiosciences, Frederick, MD). Real-time PCR analysis was performed using the RT2 Profiler Mouse Neurogenesis PCR Array (PAMM-404Z, SABiosciences) according to the manufacturer’s instructions on an ABI 7300 Real-Time PCR System (Applied Biosystems). No template controls and RT controls were on the microarray. Gene of interest (GOI) CT values were normalized to the average CT value of four housekeeping genes (β-actin, B2 m, GAPDH, Hsp90ab1), and subsequent ΔCT values were assessed using the comparative CT method (ΔΔCT) [40]. Results are expressed as fold change, 2−ΔΔCT/2ΔΔCT, where GOI-T refers to the gene of interest in a particular treatment group and GOI-C to the same gene of interest but in the control group. Fold change was measured as the ratio of the ΔΔCT under exposure conditions (e.g. arsenic or enrichment) to the ΔΔCT under control conditions (e.g. tap water or no enrichment) for a particular GOI. Fold regulation was calculated as −1/2ΔΔCT for all fold changes less than one.

Statistical Analysis

Neurogenesis data was analyzed using one-way ANOVA (SPSS, v.19; Chicago, IL) with post-hoc analysis performed as needed and corrected for multiple comparisons using Bonferroni, n = 7–9 mice.
per group. Gene expression data was analyzed using the Student’s t-test, n = 6 mice per group with Bonferroni corrections when multiple comparisons were performed.

Results

Perinatal Arsenic Exposure did not Alter Proliferation of Neural Progenitor Cells

Proliferation of neural progenitor cells (NPC) was measured using colocalization of BrdU, an exogenous S-phase marker, and Ki67, an endogenous cell proliferation marker (Figure 2A). The use of two markers was necessary, as arsenic has been shown to induce DNA damage, and BrdU may label cells with DNA damage; thus, as Ki67 expression mimics that of BrdU within the proliferative zone, it was used to confirm the BrdU+ cell counts, validate the pulse chase assay, and to ensure measurement of an actively proliferating population of neural progenitors. While it is more common to label with one or the other marker, BrdU+ only cell counts may overestimate proliferation of NPC and Ki67+ only cell counts do not give an accurate birthdate for cells. However, the disadvantage of double labeling with both BrdU and Ki67 is that cell counts do not include the very small quantity of BrdU+ labeled cells that exit the cell cycle within 12 hours of the injections; we found this amount to be negligible compared to the total counts of BrdU+Ki67+ for proliferation. The labeling method used here provides a depiction of a population of cells that includes neural stem cells and their progeny, transient amplifying cells, which can give rise to neurons. Four injections of 50 mg/kg BrdU (n = 7-9 mice/group) were given over a 12-hour period to PD34 male mice. Twelve hours after the last BrdU injection, the animals were sacrificed and adult neurogenesis was measured. Labeling with BrdU+ and Ki67+ resulted in an average of 3973±497 NPC in the DG of control animals and 3465±372 NPC in the arsenic-exposed animals (Figure 2B, 2C). Thus, arsenic-exposed mice have 13% less NPC than their control counterparts. Cells that were only labeled with BrdU or Ki67 or more than three nuclei away from the subgranular zone of the dentate gyrus were not counted as proliferating progenitor cells. One-way analysis of variance (ANOVA) assessing the effect of treatment (arsenic water versus tap water) on proliferation showed that average cell counts are not significantly different from one another. As such, perinatal exposure of 50 ppb arsenic (throughout all three trimester equivalents in mice) did not alter the proliferation of NPC in the DG of the hippocampus at PD35 (Figure 2D).

Perinatal Arsenic Exposure Reduced the Number of Differentiated Neural Progenitor Cells

Differentiation of NPC was measured using colocalization BrdU with either doublecortin (DCX), a marker of neuroblasts and immature neurons, or NeuN, a marker of mature neurons (Figures 3A, 3B). Since the impact of arsenic on the differentiation capacity of NPC is not known, we assessed overall differentiation, including the generation of neuroblasts and immature neurons (DCX+) and mature neurons (NeuN+). Differentiation was measured four weeks after the last BrdU injection to allow for maturation of BrdU-labeled cells (n = 7-9 mice/group). Figures 3A and 3B show representative images of colocalization of BrdU with DCX (BrdU+DCX+) and BrdU with NeuN (BrdU+NeuN+); both types of cell counts were used for assessment of total differentiation. Analysis of phenotype indicated that the relative amounts of each cell type were unchanged between groups: BrdU+ labeling (~25%), BrdU+DCX+ (~15%), and BrdU+NeuN+ (~60%). From the proliferation data, a significant quantity (approximately 3500) of NPC was labeled in both control and arsenic-exposed animals. In control animals, there were 1997±178 BrdU+/DCX+ and BrdU+/NeuN+ labeled cells (Figure 3C), while in the arsenic-exposed animals, there were 1178±252 BrdU+/DCX+ and BrdU+/NeuN+ labeled cells. This translates into a 41% decrease in the number of differentiated cells in arsenic-exposed animals as compared to their control counterparts (Figure 3D). One-way ANOVA revealed a significant effect of arsenic exposure on differentiation of NPC in the DG (F(1,13) = 7.311, p = .018). Thus, perinatal exposure of 50 ppb arsenic (throughout all three trimester equivalents in mice) reduced the number of differentiated NPC in the DG of the hippocampus at PD63 (Figure 3E).

Exposure to an Enriched Environment Increased Proliferation of Neural Progenitor Cells in Control Animals

Using the same BrdU injection paradigm, NPC were labeled in four sets of PD34 mice: control and arsenic-exposed animals that were exposed to enrichment and control and arsenic-exposed

Figure 5. Perinatal arsenic exposure alters genes involved in several different pathways important in neurogenesis. Each box contains genes that have altered expression in the dentate gyrus derived from adult male mice exposed to 50 ppb arsenic during development. Arrows indicate direction of expression, while red asterisks indicate genes with reversed expression after exposure to enrichment indicating restoration, doi:10.1371/journal.pone.0073720.g005

Aberrant gene expression after perinatal arsenic exposure in adult male mice

* denotes genes with reversed expression after experience in enrichment

### Abbreviations

- **BrdU**: 5-bromo-2’-deoxyuridine
- **DCX**: doublecortin
- **NeuN**: NeuN
- **NPC**: neural progenitor cells
animals that were not exposed to enrichment. After five days of daily, brief (2–4 hours) exposure to enrichment after which animals were returned to their home cages, proliferation of NPC was assessed via BrdU and Ki67 colocalization in the subgranular zone of the dentate gyrus of PD40 animals (n = 7–9 mice/group). Figure 2A shows a representative image of colocalization of BrdU with Ki67 for proliferation assessment. Assessment of proliferation resulted in 6i53.64±1372.1 BrdU+Ki67+ labeled cells in control animals exposed to enrichment; this constitutes a 70% increase over control animals not exposed to enrichment. In arsenic-exposed animals exposed to enrichment, there were 5512.96±1935.95 BrdU+Ki67+ labeled cells: this constitutes a 55% increase over arsenic-exposed animals not exposed to enrichment and a 33% increase over control animals not exposed to enrichment (Figure 4A, 4C). Figure 4A shows a representative image of the DG from an arsenic-exposed animal with experience to enrichment. One-way ANOVA indicated a significant effect of enrichment on proliferation regardless of perinatal treatment (F(1,21) = 13.87, p = .001). Using a Student’s t-test with Bonferroni correction, brief exposure to enrichment slightly increased proliferation for arsenic-exposed animals but was not significant (Figure 4C, p = .061); however, exposure to enrichment did significantly increase proliferation for control mice (Figure 4C, p = .008). There is no statistically significant difference in the average cell counts between both groups exposed to enrichment.

Regardless of perinatal exposure, NPC proliferation in the DG is enhanced after five days of brief exposure to enrichment, though this increase is only statistically significant in control animals.

**Exposure to an Enriched Environment Increased the Number of Differentiated Neural Progenitor Cells in All Animals**

Using the same BrdU injection paradigm, NPC were labeled in four sets of PD34 mice: control and arsenic-exposed animals that were exposed to enrichment for one month and control and arsenic-exposed animals that were not exposed to enrichment (n = 7–9 mice/group). After brief (2–4 hours), daily enrichment for 28 days, colocalization of BrdU with DCX (BrdU+DCX+) and BrdU with NeuN (BrdU+NeuN+) in the DG was assessed at PD63 in all four groups (Figure 3A, 3B). One-way ANOVA showed a significant effect of enrichment on differentiation for both controls and arsenic-exposed animals regardless of perinatal exposure (F(1,21) = 14.71, p = .001). Analysis of phenotype indicated no significant difference in the percent of cell types between the two groups exposed to enrichment (data not shown), similar to that seen in groups with no exposure to enrichment. For animals exposed to enrichment, colocalization revealed 2778±232 BrdU+DCX+ and BrdU+NeuN+ labeled cells in control mice, a 39% increase over control animals without exposure to enrichment. In arsenic-exposed mice with exposure to enrichment, colocalization revealed a 33% increase over control animals not exposed to enrichment. In arsenic-exposed animals exposed to enrichment, colocalization revealed a 53% increase over arsenic-exposed animals not exposed to enrichment. For animals exposed to enrichment, colocalization revealed a 53% increase over arsenic-exposed animals not exposed to enrichment. In arsenic-exposed animals exposed to enrichment, colocalization revealed a 53% increase over arsenic-exposed animals not exposed to enrichment. In arsenic-exposed animals exposed to enrichment, colocalization revealed a 53% increase over arsenic-exposed animals not exposed to enrichment.

**Table 2.** Exposure to enrichment for one month altered gene expression in control adult male mice compared to control age-matched animals without exposure to enrichment, p-value <.05.

| Accession Number | Gene Title | Gene Symbol | Fold Regulation | Function                  |
|------------------|------------|-------------|-----------------|---------------------------|
| NM_009599        | Acetylcholinesterase | Ache       | 1.188           | Apoptosis; Synaptogenesis |
| NM_009630        | Adenosine A2a receptor | Adora2a   | −1.527          | Apoptosis; GPCR Signaling |
| NM_007471        | Amyloid beta (A4) precursor protein | App        | −1.203          | Notch Signaling           |
| NM_145990        | CDK5 regulatory subunit associated protein 2 | Cdk5rap2  | −5.006          | Cell Cycle                |
| NM_009871        | Cyclin-dependent kinase 5, regulatory subunit 1 (p35) | Cdk5r1    | −1.349          | Cell Cycle                |
| NM_007864        | Discs, large homolog 4 | Dlg4       | −1.310          | Synaptic Transmission     |
| NM_010025        | Doublecortin | Dcx        | 1.193           | Axonogenesis               |
| NM_010227        | Filamin, alpha | Flna       | 1.426           | Transcription Factors      |
| NM_008169        | Glutamate receptor, ionotropic, NMDA1 | Grin1     | −1.155          | Synaptic Transmission      |
| NM_013905        | Hairpin enhancer-of-split related with YRPW motif-like | Heyl     | −1.494          | Notch Signaling           |
| NM_207225        | Histone deacetylase 4 | Hdac4     | −1.341          | Cell Cycle                |
| NM_010784        | Midkine   | Mdk         | 1.934           | Cell Cycle                |
| NM_025282        | Myocyte enhancer factor 2C | MeF2c     | 1.198           | Transcription Factors      |
| NM_018094        | Neurogenic differentiation 1 | Neurod1   | 2.344           | Transcription Factors      |
| NM_176930        | Neuron-glia-CAM-related cell adhesion molecule | Nrcam    | 1.374           | Synaptogenesis             |
| NM_010399        | Neuropilin 2 | Nrp2       | −1.188          | Cell Adhesion              |
| NM_008742        | Neurotrophin 3 | Ntf3       | 1.427           | Synaptic Transmission      |
| NM_008711        | Noggin     | Nog         | −1.962          | Axonogenesis                |
| NM_010883        | Norrie disease | Ndpl       | 1.326           | WNT Signaling              |
| NM_008714        | Notch gene homolog 1 | Notch1    | −1.422          | Notch Signaling           |
| NM_016967        | Oligodendrocyte transcription factor 2 | Olig2     | −2.664          | Growth Factor              |
| NM_008900        | POU domain, class 3, transcription factor 3 | Pou3f3   | −1.267          | Transcription Factors      |
| NM_009237        | SRY-box containing gene 3 | Sox3      | −1.537          | Transcription Factors      |
| NM_008900        | SRY-box containing gene 3 | Sox3      | −1.537          | Transcription Factors      |
| NM_011313        | S100 calcium binding protein A6 (calcyclin) | S100a6    | 2.193           | Axonogenesis                |

doi:10.1371/journal.pone.0073720.t002
enrichment, colocalization revealed 2613 ± 294 BrdU+DCX+ and BrdU+NeuN+ labeled cells, a 121% increase over arsenic-exposed animals without exposure to enrichment and a 31% increase over control animals not exposed to enrichment (Figure 4B, 4D). Figure 4B shows a representative image of the DG from an arsenic-exposed animal with one month of exposure to enrichment. Using a Student’s t-test with a Bonferroni correction, brief exposure to enrichment significantly increased differentiation for arsenic-exposed animals with one month of exposure to enrichment (Figure 4D, p = .006) and control mice exposed to enrichment significantly increased differentiation for each GOI. Fold regulation is expressed as the negative inverse for negative fold changes. A Student’s t-test was used to compare exposure conditions to control conditions. Table 1 shows gene expression of arsenic-exposed adult males compared to age-matched control animals. Of the 82 genes on the microarray, 13.4% were significantly upregulated (p < .05): these included Ache, Ache, Ach, and Ache, which are involved in apoptosis and in Alzheimer’s disease. Perinatal arsenic exposure resulted in downregulation (p < .05) of 18.3% of the genes on the array. These included genes involved in axonogenesis and neurite growth (Dcx, Tr, Robo1, Mtp2), growth factors (Ptn, Odz, Fgt2), transcription factors (Pax6 and Creb1), synaptic signaling molecules (Nf1 and Chrm2), and Notch and TGFβ signaling molecules (Ache1, H2, Nrg1, and Tgb1) as seen in Figure 5.

### Table 3. Exposure to enrichment for one month altered gene expression in arsenic-exposed adult male mice compared to arsenic-exposed age-matched animals without exposure to enrichment, p-value < .05.

| Accession Number | Gene Title | Gene Symbol | Fold Regulation | Function |
|------------------|------------|-------------|----------------|----------|
| NM_009599        | Acetylcholinesterase | Ache | −1.407 | Apoptosis; Synaptogenesis |
| NM_008553        | Achaete-scute complex homolog 1 | Ascl1 | 1.265 | Notch Signaling |
| NM_009685        | Amyloid beta (A4) precursor protein-binding, family B, member 1 | Apbb1 | −1.969 | Axon Signaling |
| NM_007554        | Bone morphogenetic protein 4 | Bmp4 | 1.616 | TGFβ Signaling |
| NM_007540        | Brain derived neurotrophic factor | Bdnf | 1.251 | Growth Factor |
| NM_133828        | CAMP responsive element binding protein 1 | Creb1 | 1.470 | Transcription Factor |
| NM_145990        | CDK5 regulatory subunit associated protein 2 | Cdk5rap2 | 2.722 | Cell Cycle |
| NM_009871        | Cyclin-dependent kinase 5, regulatory subunit 1 | Cdk5r1 | 1.196 | Cell Cycle |
| NM_010025        | Doublecortin | Dcx | 1.278 | Axon Signaling |
| NM_010113        | Epidermal growth factor | Egf | 1.670 | Growth Factor |
| NM_008006        | Fibroblast growth factor 2 | Fgf2 | 1.657 | Growth Factor |
| NM_008169        | Glutamate receptor, ionotropic, NMDA1 | Grin1 | 1.160 | Synaptic Transmission |
| NM_013904        | Hair/enhancer-of-split related with RYPW motif 2 | Hey2 | 1.426 | Notch Signaling |
| NM_207225        | Histone deacetylase 4 | Hdac4 | 1.331 | Cell Cycle |
| NM_010556        | Interleukin 3 | Il3 | 3.422 | Cytokine |
| NM_001039934     | Microtubule-associated protein 2 | Mtap2 | 1.654 | Axogenesis |
| NM_001081049     | Myeloid/lymphoid or mixed-lineage leukemia 1 | Mll1 | 1.238 | Cell Cycle |
| NM_010897        | Neurilformatinosis 1 | Nf1 | 1.579 | Synaptic Transmission |
| NM_010883        | Norrie disease | Ndp | −1.264 | WNT Signaling |
| NM_013627        | Paired box gene 6 | Pax6 | 1.487 | Transcription Factor |
| NM_008973        | Pleiotrophin | Ptn | 1.374 | Cell Cycle |
| NM_009900        | POU domain, class 3, transcription factor 3 | Pou3f3 | 1.272 | Transcription Factor |
| NM_019413        | Roundabout homolog 1 | Robo1 | 1.618 | Cell Adhesion |
| NM_022312        | Tenascin R | Tnr | 1.402 | Cell Adhesion |
| NM_011577        | Transforming growth factor, beta 1 | Tgfb1 | 1.357 | TGFβ Signaling |
| NM_007554        | Vascular endothelial growth factor A | Vegfa | 1.467 | Growth Factor |

Perinatal Arsenic Exposure Altered mRNA Expression of Neurogenesis-related Genes

To analyze several genes associated with neurogenesis, we compared gene expression profiles between control and arsenic-exposed animals using a microarray on microdissected dentate gyrus tissue from PD70 animals (n = 6 mice/group). All CT values of genes of interest (GOI) were normalized to the average CT value of four housekeeping genes (β-actin, B2 m, GAPDH, Hsp90ab1), and subsequent ΔCT values were assessed using the comparative CT method (ΔΔCT) [40]. Fold change was measured as 2−ΔΔCT(arsenic or enrichment)/2−ΔΔCT (control or no enrichment) for each GOI. Fold regulation is expressed as the negative inverse for negative fold changes. A Student’s t-test was used to compare exposure conditions to control conditions. Table 1 shows gene expression of arsenic-exposed adult males compared to age-matched control animals. Of the 82 genes on the microarray, 13.4% were significantly upregulated (p < .05): these included Apb1, Apoe, Ntn, Ache, and Adora1, which are involved in apoptosis and in Alzheimer’s disease. Perinatal arsenic exposure resulted in downregulation (p < .05) of 18.3% of the genes on the array. These included genes involved in axonogenesis and neurite growth (Dcx, Tr, Robo1, Mtp2), growth factors (Ptn, Odz, Fgt2), transcription factors (Pax6 and Creb1), synaptic signaling molecules (Nf1 and Chrm2), and Notch and TGFβ signaling molecules (Ache1, H2, Nrg1, and Tgb1) as seen in Figure 5.

### Exposure to an Enriched Environment Reversed Altered mRNA Expression in Arsenic-exposed Animals

After one month of brief, daily exposure (2–4 hours per day) to an enriched environment, mRNA expression for neurogenesis-related genes was analyzed on dentate gyrus tissue derived from adult male mice aged PD70 (n = 6 mice/group). Genes that were significantly altered (p < .05) after this enrichment paradigm are displayed in Table 2 for control animals and Table 3 for arsenic-
Table 4. Reversal of altered gene expression after one month exposure to an enriched environment compared to arsenic-exposed animals without exposure to enrichment, p-value <.05.

| Gene Symbol | Perinatal Arsenic Exposure compared to controls | Perinatal Arsenic Exposure with EE compared to column A | Control (no perinatal exposure) with EE compared to column A |
|-------------|-----------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------|
| Aplbb1      | 3.042                                         | −1.969                                                 | −3.697                                                        |
| Ache        | 1.676                                         | −1.407                                                 | −1.287                                                        |
| Ndp         | 1.312                                         | −1.264                                                 | no change                                                     |
| Dcx         | −1.230                                        | 1.278                                                  | 1.608                                                         |
| Ptn         | −1.256                                        | 1.374                                                  | 1.547                                                         |
| Tgfb1       | −1.320                                        | 1.357                                                  | 1.399                                                         |
| Tnr         | −1.338                                        | 1.402                                                  | 1.365                                                         |
| Fgf2        | −1.371                                        | 1.657                                                  | 1.417                                                         |
| Asc1        | −1.374                                        | 1.265                                                  | 1.555                                                         |
| Pax6        | −1.390                                        | 1.487                                                  | 1.760                                                         |
| Creb1       | −1.468                                        | 1.470                                                  | 1.547                                                         |
| Hey2        | −1.536                                        | 1.426                                                  | 1.684                                                         |
| Robo1       | −1.552                                        | 1.618                                                  | 1.528                                                         |
| Nf1         | −1.666                                        | 1.579                                                  | 1.781                                                         |
| Mtap2       | −1.870                                        | 1.654                                                  | 1.942                                                         |

Column A

doi:10.1371/journal.pone.0073720.t004

Discussion

It is widely recognized that high levels of arsenic produce deleterious effects on the brain. The results presented here demonstrate that our developmental arsenic exposure model, which represents a low and environmentally relevant concentration previously considered safe, significantly impacts adult neurogenesis, specifically the number of differentiated NPC in the SGZ. Given that our labeling method is more likely to underestimate the total degree of neurogenesis [35] (as it does not include BrdU+ only cells that have exited the cell cycle after 12 hours for proliferation assessment), the fact that we were able to discern a difference of 13% for proliferation (though not significant) and 41% for differentiation after perinatal arsenic exposure in the adult animal is substantive. Our subsequent studies will further elucidate arsenic’s impact on the immature cells (DCX+) and mature cells (NeuN+) separately and on NPC survival. Because adult neurogenesis has been shown to be integral for certain forms of learning and memory, the hippocampal damage measured in this study may be responsible for the cognitive deficits previously observed in this arsenic exposure model.

Other heavy metals similar to arsenic have been implicated in reduced adult neurogenesis and deficits in cognition. A single injection of 5 μg methylmercury per gram body weight at PD7, resulting in 500 ppb concentration in the brain, was enough to reduce adult neurogenesis and hippocampal size and induce hippocampal-dependent learning and memory deficits specifically in a spatial learning task [27]. Using tritiated thymidine incorporation at PD7, the authors were also able to show inhibited hippocampal DNA synthesis, degradation of cyclin E, and reduced cyclin D1 and D3 during postnatal development in which neurogenesis is highly active in the hippocampus [27]. Mercury is a potent neurotoxin and elevated exposures may lead to mental retardation; yet, this brief exposure resulted in significant morphological changes and learning deficits similar to the results we report here using an arsenic concentration an order of magnitude lower than that used in the methylmercury study. Similarly, postnatal exposure to low levels of lead (0.2% lead acetate resulting in 6 ng Pb/g brain by PD80) from PD1 to PD30 results in increased anxiety behavior, deficits in contextual fear conditioning, reduced adult neurogenesis (specifically differentiation), and preferential astroglial lineage in PD80 Wistar rats [24]. Another study using the same low level of lead acetate exposure from GD16 to PD21, resulting in 35–40 ppm Pb in blood, showed altered differentiation of adult neurogenesis at PD110 but no learning deficits in the Morris water maze [26]. Chronic exposure during development using an environmentally relevant dose of lead (1500 ppm lead acetate resulting in 258 ppm Pb in blood) results in significantly decreased proliferation and survival of granule cells and reduced mossy fiber input into CA3 region of the hippocampus from the dentate, possibly accounting for the deficits in synaptic plasticity and learning seen in lead-exposed animals [25]. Our results reveal that like mercury and lead, developmental
Table 5. Expression of neurogenesis-related genes in arsenic-exposed adult male mice compared to control age-matched animals, entire data set including non-significant changes.

| Accession Number | Gene Title                                                                 | Gene Symbol | Fold Change | p-value |
|------------------|------------------------------------------------------------------------------|-------------|-------------|---------|
| NM_009599        | Acetylcholinesterase                                                        | Ache        | 1.68        | 0.001   |
| NM_001008533     | Adenosine A1 receptor                                                       | Adora1      | 1.14        | 0.03    |
| NM_009630        | Adenosine A2a receptor                                                      | Adora2a     | 1.25        | 0.27    |
| NM_007439        | Anaplastic lymphoma kinase                                                  | Alk         | 1.49        | 0.06    |
| NM_009685        | Amyloid beta (A4) precursor protein-binding, family B, member 1            | Apbb1       | 3.04        | 0.00    |
| NM_009696        | Apolipoprotein E                                                           | Apoe        | 1.98        | 0.01    |
| NM_007471        | Amyloid beta (A4) precursor protein                                         | App         | 1.13        | 0.22    |
| NM_009711        | Artemin                                                                    | Artn        | 1.03        | 0.90    |
| NM_008553        | Achaete-scute complex homolog 1 (Drosophila)                              | Ascl1       | 0.73        | 0.002   |
| NM_009741        | B-cell leukemia/lymphoma 2                                                 | Bcl2        | 0.86        | 0.13    |
| NM_007540        | Brain derived neurotrophic factor                                          | Bdnf        | 0.82        | 0.41    |
| NM_007553        | Bone morphogenetic protein 2                                               | Bmp2        | 1.21        | 0.48    |
| NM_007554        | Bone morphogenetic protein 4                                               | Bmp4        | 0.79        | 0.09    |
| NM_007559        | Bone morphogenetic protein 8b                                              | Bmp8b       | 0.80        | 0.38    |
| NM_009871        | Cyclin-dependent kinase 5, regulatory subunit 1 (p35)                      | Cdk5r1      | 0.87        | 0.08    |
| NM_145990        | CDK5 regulatory subunit associated protein 2                               | Cdk5rap2    | 0.47        | 0.16    |
| NM_203491        | Cholinergic receptor, muscarinic 2, cardiac                                 | Chrm2       | 0.49        | 0.05    |
| NM_133828        | CAMP responsive element binding protein 1                                 | Creb1       | 0.68        | 0.01    |
| NM_008176        | Chemokine (C-X-C motif) ligand 1                                           | Cxcl1       | 0.86        | 0.69    |
| NM_010025        | Doublecortin                                                               | Dcx         | 0.81        | 0.02    |
| NM_007864        | Discs, large homolog 4 (Drosophila)                                       | Dlg4        | 1.11        | 0.34    |
| NM_007865        | Delta-like 1 (Drosophila)                                                  | Dll1        | 2.34        | 0.02    |
| NM_010077        | Dopamine receptor D2                                                       | Drd2        | 1.65        | 0.02    |
| NM_007889        | Dishevelled 3, dsh homolog (Drosophila)                                    | Dvl3        | 1.14        | 0.29    |
| NM_010110        | Ephrin B1                                                                  | Efnb1       | 1.28        | 0.05    |
| NM_010113        | Epidermal growth factor                                                    | Egf         | 0.93        | 0.70    |
| NM_177821        | E1A binding protein p300                                                    | Ep300       | 0.78        | 0.07    |
| NM_001003817     | V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | Erbb2 | 1.06 | 0.80 |
| NM_008006        | Fibroblast growth factor 2                                                  | Fgf2        | 0.73        | 0.001   |
| NM_010227        | Filamin, alpha                                                             | Flna        | 1.75        | 0.01    |
| NM_010275        | Glial cell line derived neurotrophic factor                                | Gdnf        | 0.96        | 0.88    |
| NM_008155        | Glucose phosphate isomerase 1                                              | Gpi1        | 1.24        | 0.06    |
| NM_008169        | Glutamate receptor, ionotropic, NMDA1 (zeta 1)                             | Grin1       | 1.13        | 0.14    |
| NM_207225        | Histone deacetylase 4                                                      | Hdac4       | 0.86        | 0.29    |
| NM_008235        | Hairy and enhancer of split 1 (Drosophila)                                 | Hes1        | 1.09        | 0.64    |
| NM_010423        | Hairy/enhancer-of-split related with YRPW motif 1                          | Hey1        | 1.21        | 0.13    |
| NM_013904        | Hairy/enhancer-of-split related with YRPW motif 2                          | Hey2        | 0.65        | 0.03    |
| NM_013905        | Hairy/enhancer-of-split related with YRPW motif-like                       | Heyl        | 0.96        | 0.81    |
| NM_010556        | Interleukin 3                                                               | Il3         | 0.69        | 0.59    |
| NM_010784        | Midkine                                                                    | Mdk         | 1.48        | 0.20    |
| NM_025282        | Myocyte enhancer factor 2C                                                 | Mef2c       | 1.32        | 0.07    |
| NM_001081049     | Myeloid/lymphoid or mixed-lineage leukemia 1                               | Mll1        | 0.99        | 0.92    |
| NM_001039934     | Microtubule-associated protein 2                                           | Mtap2       | 0.53        | 0.01    |
| NM_010882        | Necdin                                                                     | Ndn         | 1.84        | 0.14    |
| NM_010883        | Norrie disease (pseudogioma) (human)                                       | Ndp         | 1.31        | 0.00    |
| NM_010894        | Neurogenic differentiation 1                                               | Neurod1     | 1.05        | 0.87    |
| NM_010896        | Neurogenin 1                                                                | Neurog1     | 2.19        | 0.06    |
| NM_009718        | Neurogenin 2                                                                | Neurog2     | 1.97        | 0.09    |
arsenic exposure can induce potent morphological damage in the adult hippocampus even at a low concentration, and these deficits may be linked to altered behavioral changes seen in our model as we have previously reported [8,13].

In vitro studies investigating the effects of developmental arsenic exposure in the parts per billion range (up to 4 μM) have shown altered cell cycling including reduced viability, minimal apoptosis, and an increase in caspase 3/7 resulting in inhibition of cell cycle progression in primary embryonic rat midbrain neuroepithelial cells [11]. Other in vitro work with P19 mouse embryonic stem cells (ESC) has demonstrated that low concentrations of arsenic in the ppb range (0.1 up to 1.0 μM sodium arsenite) suppress the differentiation, but not proliferation, of ESC into neurons indicated by reduced Tuj1, neurogenin 1, neurogenin 2, and NeuroD expression in arsenic-treated cells [41]. The results from these studies concur with our in vivo developmental model of arsenic exposure and the work presented here, suggesting that arsenic impacts the number of differentiated cells among several cell types both in vivo and in vitro.

Exposure to higher concentrations of arsenic (ppm range up to 68 mg/L) during adulthood results in changes in synaptic plasticity components, including the expression of the NMDA receptor subunit NR2A, PSD-95, and pCaMKIIα in the hippocampus, all of which are important for learning and memory [42]. In accordance with our own previous results [43], increased SynGAP, a negative regulator of Ras/MAPK activity, along with decreased pERK1/2 activity is also seen after chronic low dose arsenic exposure in the adult. Two months of 4.0 mg/L As2O3

### Table 5. Cont.

| Accession Number | Gene Title               | Gene Symbol | Fold Change | p-value |
|------------------|--------------------------|-------------|-------------|---------|
| NM_010897        | Neurofibromatosis 1      | Nf1         | 0.60        | 0.04    |
| NM_008711        | Noggin                   | Nog         | 1.65        | 0.05    |
| NM_008714        | Notch gene homolog 1     | Notch1      | 0.98        | 0.92    |
| NM_010928        | Notch gene homolog 2     | Notch2      | 1.08        | 0.46    |
| NM_013708        | Nuclear receptor subfamily 2, group E, member 3 | Ne2e3 | 1.17 | 0.66 |
| NM_176930        | Neuron-glia-CAM-related cell adhesion molecule | Nrcam | 1.10 | 0.30 |
| NM_178591        | Neuregulin 1             | Ng1         | 0.62        | 0.01    |
| NM_008737        | Neuregulin 1             | Nrp1        | 0.86        | 0.62    |
| NM_010939        | Neuregulin 2             | Nrp2        | 1.02        | 0.79    |
| NM_008742        | Neurotrophin 3           | Ntf3        | 1.09        | 0.46    |
| NM_008744        | Nettin 1                 | Ntn1        | 1.91        | 0.02    |
| NM_011855        | Odd Oz/ten-m homolog 1   | Odz1        | 0.80        | 0.05    |
| NM_016967        | Oligodendrocyte transcription factor 2 | Olig2 | 1.58 | 0.07 |
| NM_013625        | Platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 | Pahb1b1 | 0.99 | 0.97 |
| NM_033620        | Par-3 (partitioning defective 3) homolog (C. elegans) | Pard3 | 0.97 | 0.71 |
| NM_008781        | Paired box gene 3        | Pax3        | Undetermined | N/A    |
| NM_008782        | Paired box gene 5        | Pax5        | 1.13        | 0.65    |
| NM_013627        | Paired box gene 6        | Pax6        | 0.72        | 0.02    |
| NM_008900        | POU domain, class 3, transcription factor 3 | Pou3f3 | 0.92 | 0.47 |
| NM_011143        | POU domain, class 4, transcription factor 1 | Pou4f1 | 1.30 | 0.47 |
| NM_008973        | Pleiotrophin             | Ptn         | 0.80        | 0.02    |
| NM_009387        | RAS-related C3 botulinum substrate 1 | Rac1 | 1.04 | 0.91 |
| NM_019413        | Roundabout homolog 1     | Robo1       | 0.64        | 0.01    |
| NM_194053        | Reticulin 4              | Rtn4        | 0.97        | 0.76    |
| NM_011313        | S100 calcium binding protein A6 (calcyclin) | S100a6 | 1.43 | 0.25 |
| NM_009115        | S100 protein, beta polypeptide, neural | S100b | 1.08 | 0.72 |
| NM_009170        | Sonic hedgehog           | Shh         | 0.74        | 0.12    |
| NM_178804        | Slit homolog 2 (Drosophila) | Slit2 | 0.86 | 0.39 |
| NM_011434        | Superoxide dismutase 1, soluble | Sod1 | 1.04 | 0.87 |
| NM_011443        | SRY-box containing gene 2 | Sox2 | 1.59 | 0.07 |
| NM_009237        | SRY-box containing gene 3 | Sox3 | 1.00 | 0.99 |
| NM_011486        | Signal transducer and activator of transcription 3 | Stat3 | 0.90 | 0.21 |
| NM_011577        | Transforming growth factor, beta 1 | Tgfβ1 | 0.76 | 0.03 |
| NM_009377        | Tyrosine hydroxylase     | Th          | 0.90        | 0.69    |
| NM_022312        | Tenascin R               | Tnr         | 0.75        | 0.001   |
| NM_009505        | Vascular endothelial growth factor A | Vegfa | 0.78 | 0.08 |

doi:10.1371/journal.pone.0073720.t005
Table 6. Expression of neurogenesis-related genes in control adult male mice after brief, daily exposure to enrichment for one month compared to control age-matched animals without exposure to enrichment.

| Accession Number | Gene Title                                      | Gene Symbol | Fold Change | p-value |
|------------------|-------------------------------------------------|-------------|-------------|---------|
| NM_009599        | Acetylcholinesterase                            | Ache        | 1.19        | 0.03    |
| NM_001008533     | Adenosine A1 receptor                           | Adora1      | 0.94        | 0.26    |
| NM_009630        | Adenosine A2a receptor                          | Adora2a     | 0.65        | 0.01    |
| NM_007439        | Anaplastic lymphoma kinase                      | Alk         | 0.68        | 0.07    |
| NM_009685        | Amyloid beta (A4) precursor protein-binding, family B, member 1 | Apbb1 | 0.75 | 0.49 |
| NM_009696        | Apolipoprotein E                                | Apoe        | 0.85        | 0.54    |
| NM_007471        | Amyloid beta (A4) precursor protein             | App         | 0.83        | 0.05    |
| NM_009711        | Artemin                                         | Artn        | 1.17        | 0.45    |
| NM_008553        | Achaete-scute complex homolog 1 (Drosophila)    | Ascl1       | 1.03        | 0.64    |
| NM_009741        | B-cell leukemia/lymphoma 2                      | Bcl2        | 1.05        | 0.54    |
| NM_007540        | Brain derived neurotrophic factor               | Bdnf        | 1.66        | 0.10    |
| NM_007553        | Bone morphogenetic protein 2                    | Bmp2        | 0.96        | 0.86    |
| NM_007554        | Bone morphogenetic protein 4                    | Bmp4        | 1.39        | 0.09    |
| NM_007559        | Bone morphogenetic protein 8b                   | Bmp8b       | 0.90        | 0.51    |
| NM_009871        | Cyclin-dependent kinase 5, regulatory subunit 1 (p35) | Cdk5rap1  | 0.74 | 0.0003 |
| NM_145990        | CDK5 regulatory subunit associated protein 2     | Cdk5rap2    | 0.20        | 0.03    |
| NM_203491        | Cholinergic receptor, muscarinic 2, cardiac      | Chrm2       | 0.70        | 0.19    |
| NM_133828        | CAMP responsive element binding protein 1       | Creb1       | 0.96        | 0.57    |
| NM_008176        | Chemokine (C-X-C motif) ligand 1                | Cxcl1       | 0.63        | 0.12    |
| NM_010025        | Doublecortin                                    | Dcx         | 1.19        | 0.04    |
| NM_007864        | Discs, large homolog 4 (Drosophila)             | Dlg4        | 0.76        | 0.03    |
| NM_007865        | Delta-like 1 (Drosophila)                       |Dll1        | 0.65        | 0.30    |
| NM_010077        | Dopamine receptor D2                            | Drd2        | 0.76        | 0.28    |
| NM_007889        | Dishevelled 3, dsh homolog (Drosophila)         | Dvl3        | 1.01        | 0.92    |
| NM_010110        | Ephrin B1                                       | Efnb1       | 0.84        | 0.08    |
| NM_010113        | Epidermal growth factor                         | Egf         | 1.30        | 0.13    |
| NM_177821        | E1A binding protein p300                        | Ep300       | 1.01        | 0.91    |
| NM_001003817     | V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | Erbb2 | 0.92 | 0.44 |
| NM_008006        | Fibroblast growth factor 2                      | Fgf2        | 0.94        | 0.62    |
| NM_010227        | Filamin, alpha                                  | Flna        | 1.43        | 0.01    |
| NM_010275        | Glial cell line derived neurotrophic factor      | Gdnf        | 0.91        | 0.72    |
| NM_008155        | Glucose phosphate isomerase 1                   | Gpi1        | 1.02        | 0.71    |
| NM_008169        | Glutamate receptor, ionotropic, NMDA1 (zeta 1)   | Grin1       | 0.87        | 0.05    |
| NM_207225        | Histone deacetylase 4                           | Hdac4       | 0.75        | 0.04    |
| NM_008235        | Hairy and enhancer of split 1 (Drosophila)      | Hes1        | 1.15        | 0.15    |
| NM_010423        | Hairy/enhancer-of-split related with YRPW motif 1 | Hey1 | 0.96 | 0.64 |
| NM_013904        | Hairy/enhancer-of-split related with YRPW motif 2 | Hey2 | 1.00 | 1.00 |
| NM_013905        | Hairy/enhancer-of-split related with YRPW motif-like | Heyl | 0.67 | 0.02 |
| NM_010556        | Interleukin 3                                   | Il3         | 0.62        | 0.54    |
| NM_010784        | Midkine                                         | Mdk         | 1.93        | 0.04    |
| NM_025282        | Myocyte enhancer factor 2C                      | Mef2c       | 1.20        | 0.04    |
| NM_001081049     | Myeloid/lymphoid or mixed-lineage leukemia 1     | Mll1        | 1.15        | 0.07    |
| NM_001039934     | Microtubule-associated protein 2                 | Mtap2       | 0.95        | 0.70    |
| NM_010882        | Necdin                                          | Ndn         | 0.98        | 0.94    |
| NM_010883        | Norrie disease (pseudoglioma) (human)           | Ndp         | 1.33        | 0.003   |
| NM_010894        | Neurogenic differentiation 1                    | Neurod1     | 2.34        | 0.03    |
| NM_010896        | Neurogenin 1                                    | Neurog1     | 1.09        | 0.88    |
| NM_009718        | Neurogenin 2                                    | Neurog2     | 0.55        | 0.19    |
(ppm range) exposure beginning at four months of age decreases both proliferation and differentiation of newly labeled cells in the dentate gyrus in mice [44]. This deficit was ameliorated after two months of drinking distilled water, suggesting that the effects of arsenic are transient. Our model indicates that significant changes in differentiation can be measured several weeks after developmental 50 ppb arsenic exposure, suggesting that the effect is not transient. It is possible that because arsenic is present during development of the brain, arsenic’s effects are much longer lasting than those seen during adulthood exposure due to arsenic-induced molecular changes. For example, low concentrations of arsenic during development impact the epigenetic status of histones and DNA, which play an important role in gene expression regulation; these epigenetic changes are concurrent with learning deficits seen in certain behavior tasks [45,46]. Thus, we hypothesize that behavioral deficits seen during adulthood of mice developmentally exposed to arsenic are due, in part, to lack of differentiated cells necessary for hippocampal-dependent learning.

To support the differences in adult neurogenesis we observed in arsenic-exposed animals, we sought to elucidate if there was transcriptional dysregulation of genes involved in adult neurogenesis in the dentate gyrus. In accordance with our morphological findings, arsenic exposure during the perinatal period resulted in downregulation of 15 target genes (18%) and upregulation of 11 target genes (13%) in adult animals.

| Accession Number | Gene Title | Gene Symbol | Fold Change | p-value |
|------------------|------------|-------------|-------------|---------|
| NM_010897        | Neurofibromatosis 1 | Nf1         | 0.97        | 0.88    |
| NM_098711        | Noggin     | Nog         | 0.51        | 0.04    |
| NM_008714        | Notch gene homolog 1 (Drosophila) | Notch1      | 0.70        | 0.01    |
| NM_010928        | Notch gene homolog 2 (Drosophila) | Notch2      | 1.09        | 0.37    |
| NM_013708        | Nuclear receptor subfamily 2, group E, member 3 | Nr2e3       | 0.50        | 0.09    |
| NM_176930        | Neuron-glia-CAM-related cell adhesion molecule | NrCAM       | 1.37        | 0.01    |
| NM_178591        | Neuregulin 1 | Nrg1        | 1.05        | 0.75    |
| NM_008737        | Neurepilin 1 | Nrp1        | 1.46        | 0.10    |
| NM_010939        | Neurepilin 2 | Nrp2        | 0.84        | 0.06    |
| NM_008742        | Neurotrophin 3 | Ntf3        | 1.43        | 0.004   |
| NM_008744        | Netrin 1    | Ntn1        | 1.43        | 0.20    |
| NM_011855        | Odd Oz/ten-m homolog 1 (Drosophila) | Odz1        | 0.87        | 0.18    |
| NM_016967        | Oligodendrocyte transcription factor 2 | Olig2       | 0.38        | 0.02    |
| NM_013625        | Platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 | Padjahb1    | 1.60        | 0.13    |
| NM_033620        | Par-3 (partitioning defective 3) homolog (C. elegans) | Pard3       | 1.15        | 0.12    |
| NM_008781        | Paired box gene 3 | Pax3        | Undetermined | N/A     |
| NM_008782        | Paired box gene 5 | Pax5        | 0.90        | 0.69    |
| NM_013627        | Paired box gene 6 | Pax6        | 1.15        | 0.25    |
| NM_008900        | POU domain, class 3, transcription factor 3 | Pou3f3      | 0.79        | 0.002   |
| NM_011143        | POU domain, class 4, transcription factor 1 | Pou4f1      | 0.74        | 0.47    |
| NM_008973        | Pleiotrophin | Ptn         | 1.12        | 0.26    |
| NM_009007        | RAS-related C3 botulinum substrate 1 | Rac1        | 1.65        | 0.08    |
| NM_019413        | Roundabout homolog 1 (Drosophila) | Robo1       | 0.90        | 0.29    |
| NM_194053        | Reticulin 4 | Rtn4        | 0.94        | 0.37    |
| NM_011313        | S100 calcium binding protein A6 (calcyclin) | S100a6      | 2.19        | 0.02    |
| NM_009115        | S100 protein, beta polypeptide, neural | S100b       | 1.45        | 0.11    |
| NM_009170        | Sonic hedgehog | Shh        | 0.81        | 0.21    |
| NM_178804        | Silh homolog 2 (Drosophila) | Silt2       | 0.72        | 0.07    |
| NM_011434        | Superoxide dismutase 1, soluble | Sod1        | 1.37        | 0.21    |
| NM_011443        | SRY-box containing gene 2 | Sox2        | 0.81        | 0.45    |
| NM_009237        | SRY-box containing gene 3 | Sox3        | 0.65        | 0.01    |
| NM_011486        | Signal transducer and activator of transcription 3 | Stat3       | 0.93        | 0.26    |
| NM_011577        | Transforming growth factor, beta 1 | Tgfb1       | 0.97        | 0.79    |
| NM_009377        | Tyrosine hydroxylase | Th          | 0.59        | 0.13    |
| NM_022312        | Tenascin R | Tnr         | 0.93        | 0.32    |
| NM_009505        | Vascular endothelial growth factor A | Vegfa       | 0.82        | 0.02    |

entire data set including non-significant changes.

doi:10.1371/journal.pone.0073720.t006
Table 7. Expression of neurogenesis-related genes in arsenic-exposed adult male mice after brief, daily exposure to enrichment for one month compared to arsenic-exposed age-matched animals without exposure to enrichment.

| Accession Number | Gene Title                                      | Gene Symbol | Fold Change | p-value |
|------------------|-------------------------------------------------|-------------|-------------|---------|
| NM_009599        | Acetylcholinesterase                            | Ache        | 0.71        | 0.001   |
| NM_001008533     | Adenosine A1 receptor                            | Adora1      | 1.04        | 0.49    |
| NM_009630        | Adenosine A2a receptor                           | Adora2a     | 1.11        | 0.62    |
| NM_007439        | Anaplastic lymphoma kinase                       | Alk         | 0.95        | 0.77    |
| NM_009685        | Amyloid beta (A4) precursor protein-binding, family B, member 1 | Apbb1 | 0.51 | 0.01 |
| NM_009696        | Apolipoprotein E                                 | Apoe        | 0.76        | 0.18    |
| NM_007471        | Amyloid beta (A4) precursor protein              | App         | 0.98        | 0.84    |
| NM_009711        | Arten                                           | Artn        | 1.10        | 0.57    |
| NM_008553        | Achaete-scute complex homolog 1 (Drosophila)    | Ascl1       | 1.27        | 0.03    |
| NM_009741        | B-cell leukemia/lymphoma 2                       | Bcl2        | 1.15        | 0.23    |
| NM_007540        | Brain derived neurotrophic factor                | Bdnf        | 1.25        | 0.05    |
| NM_007553        | Bone morphogenetic protein 2                    | Bmp2        | 1.08        | 0.69    |
| NM_007554        | Bone morphogenetic protein 4                    | Bmp4        | 1.62        | 0.001   |
| NM_007559        | Bone morphogenetic protein 8b                   | Bmp8b       | 2.04        | 0.10    |
| NM_009871        | Cyclin-dependent kinase 5, regulatory subunit 1 (p35) | Cdk5r1  | 1.20 | 0.02 |
| NM_145990        | CDK5 regulatory subunit associated protein 2     | Cdk5rap2    | 2.72        | 0.05    |
| NM_203491        | Cholinergic receptor, muscarinic 2, cardiac      | Chrm2       | 1.65        | 0.15    |
| NM_133828        | CAMP responsive element binding protein 1       | Creb1       | 1.47        | 0.01    |
| NM_008176        | Chemokine (C-X-C motif) ligand 1                 | Cxcl1       | 0.66        | 0.44    |
| NM_010025        | Doublecortin                                     | Dcx         | 1.28        | 0.03    |
| NM_007864        | Discs, large homolog 4 (Drosophila)             | Dlg4        | 1.19        | 0.21    |
| NM_007865        | Delta-like 1 (Drosophila)                       | Dll1        | 0.69        | 0.21    |
| NM_010077        | Dopamine receptor D2                             | Drd2        | 0.77        | 0.25    |
| NM_007889        | Dishevelled 3, dsh homolog (Drosophila)         | Dvl3        | 1.01        | 0.96    |
| NM_010110        | Ephrin B1                                       | Efnb1       | 0.89        | 0.37    |
| NM_010113        | Epidermal growth factor                          | Egf         | 1.67        | 0.03    |
| NM_177821        | E1A binding protein p300                         | Ep300       | 1.28        | 0.09    |
| NM_001003817     | V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | Erbb2 | 1.27 | 0.19 |
| NM_008006        | Fibroblast growth factor 2                      | Fgf2        | 1.66        | 0.00    |
| NM_010227        | Filamin, alpha                                   | Flna        | 0.86        | 0.34    |
| NM_010275        | Glial cell line derived neurotrophic factor      | Gdnf        | 1.38        | 0.33    |
| NM_008155        | Glucose phosphate isomerase 1                   | Gpi1        | 0.90        | 0.19    |
| NM_008169        | Glutamate receptor, ionotropic, NMDA1 (zeta 1)   | Grin1       | 1.16        | 0.04    |
| NM_207225        | Histone deacetylase 4                            | Hdac4       | 1.33        | 0.05    |
| NM_008235        | Hairy and enhancer of split 1 (Drosophila)      | Hes1        | 0.90        | 0.51    |
| NM_010423        | Hairy/enhancer-of-split related with YRPW motif 1 | Hey1   | 0.96 | 0.77 |
| NM_013904        | Hairy/enhancer-of-split related with YRPW motif 2 | Hey2   | 1.43 | 0.05 |
| NM_013905        | Hairy/enhancer-of-split related with YRPW motif-like | Heyl   | 1.09 | 0.56 |
| NM_010556        | Interleukin 3                                    | Il3         | 3.42        | 0.04    |
| NM_010784        | Midkine                                         | Mdk         | 0.70        | 0.20    |
| NM_025282        | Myocyte enhancer factor 2C                      | Mef2c       | 0.80        | 0.25    |
| NM_001081049     | Myeloid/lymphoid or mixed-lineage leukemia 1     | Mil1        | 1.24        | 0.02    |
| NM_001039934     | Microtubule-associated protein 2                 | Mtap2       | 1.65        | 0.01    |
| NM_010882        | Necdin                                          | Ndn         | 0.71        | 0.18    |
| NM_010883        | Norrie disease (pseudoglioma) (human)            | Ndp         | 0.79        | 0.03    |
| NM_010894        | Neurogenic differentiation 1                    | Neurod1     | 0.85        | 0.44    |
| NM_010896        | Neurogenin 1                                    | Neurog1     | 0.88        | 0.75    |
| NM_009718        | Neurogenin 2                                    | Neurog2     | 0.77        | 0.40    |
Upregulation of genes included those involved with apoptosis (Ntn1, Adora1, and Ache) and Alzheimer’s disease (ApoE, Apbb1). In particular, acetylcholinesterase (Ache) is an important regulator of apoptosis; increased expression, while not initiating apoptosis, has been correlated with apoptotic cells [47]. Adult arsenic exposure (20 mg/kg body weight for 28 days in rats) results in decreased activity of acetylcholinesterase in the hippocampus, but also decreased binding of (3)H-QNB, a label of muscarinic-cholinergic receptors [48]. While the increase in Ache mRNA is not indicative of greater activity of the enzyme, it could be overcompensating for a disruption in cholinergic signaling as suggested by the significantly reduced Chrm2 mRNA, a muscarinic cholinergic receptor (Table 1). The hippocampus receives several cholinergic inputs that may contribute to the formation of new neurons; additionally, cholinergic transmission is important for learning and memory and altered acetylcholine levels have been associated Alzheimer’s-related cognitive deficits [49]. Thus, aberrant cholinergic transmission induced by arsenic could play a part in reduced adult neurogenesis seen in our studies, along with upregulation of the genes Apbb1 and ApoE, both of which are associated with Alzheimer’s disease and have been shown to impair adult neurogenesis [50].

Additionally, while adult exposure to low concentrations of arsenic does not induce apoptosis in the hippocampus [44], developmental exposure to arsenic increases apoptosis in conjunction with decreased Nissl body staining in neuronal bodies in the entire data set including non-significant changes.

do i:10.1371/journal.pone.0073720.t007

| Accession Number | Gene Title | Gene Symbol | Fold Change | p-value |
|------------------|------------|-------------|-------------|---------|
| NM_010897        | Neurofibromatosis 1 | Nf1          | 1.58        | 0.01    |
| NM_008711        | Noggin     | Nog         | 0.82        | 0.40    |
| NM_008714        | Notch gene homolog 1 (Drosophila) | Notch1       | 1.24        | 0.21    |
| NM_010928        | Notch gene homolog 2 (Drosophila) | Notch2       | 1.11        | 0.45    |
| NM_013708        | Nuclear receptor subfamily B, group E, member 3 | Nrb3         | 1.40        | 0.48    |
| NM_176930        | Neuron-glia-CAM-related cell adhesion molecule | Nrcam        | 0.91        | 0.08    |
| NM_178591        | Neuregulin 1 | Nrg1        | 1.24        | 0.16    |
| NM_008737        | Neuropilin 1 | Nrp1        | 1.18        | 0.35    |
| NM_010939        | Neuropilin 2 | Nrp2        | 1.22        | 0.22    |
| NM_008742        | Neurotrophin 3 | Ntf3        | 0.88        | 0.24    |
| NM_008744        | Netrin 1    | Ntn1        | 0.80        | 0.22    |
| NM_011855        | Odd Oz/ten-m homolog 1 (Drosophila) | Oddz1        | 1.26        | 0.12    |
| NM_016967        | Oligodendrocyte transcription factor 2 | Olig2        | 0.89        | 0.62    |
| NM_013625        | Platelet-activating factor acetylhydrolase, isoform 1b, subunit 1 | Pafah1b1    | 0.85        | 0.48    |
| NM_033620        | Par-3 (partitioning defective 3) homolog (C. elegans) | Pard3        | 1.29        | 0.09    |
| NM_008781        | Paired box gene 3 | Pax3        | Undetermined | N/A |
| NM_008782        | Paired box gene 5 | Pax5        | 0.93        | 0.76    |
| NM_013627        | Paired box gene 6 | Pax6        | 1.49        | 0.02    |
| NM_008900        | POU domain, class 3, transcription factor 3 | Pou3f3      | 1.27        | 0.03    |
| NM_011143        | POU domain, class 4, transcription factor 1 | Pou4f1      | 1.33        | 0.48    |
| NM_008973        | Pleiotrophin | Ptn         | 1.37        | 0.0003  |
| NM_009007        | RAS-related C3 botulinum substrate 1 | Rac1        | 0.87        | 0.54    |
| NM_019413        | Roundabout homolog 1 (Drosophila) | Robo1       | 1.62        | 0.01    |
| NM_194053        | Reticulon 4 | Rtn4        | 1.13        | 0.14    |
| NM_011313        | S100 calcium binding protein A6 (calcyclin) | S100a6      | 0.69        | 0.12    |
| NM_009115        | S100 protein, beta polypeptide, neural | S100b       | 0.97        | 0.88    |
| NM_009170        | Sonic hedgehog | Shh         | 0.91        | 0.21    |
| NM_178804        | Slit homolog 2 (Drosophila) | Slit2       | 1.04        | 0.72    |
| NM_011434        | Superoxide dismutase 1, soluble | Sod1        | 0.87        | 0.38    |
| NM_011443        | SRY-box containing gene 2 | Sox2        | 0.89        | 0.63    |
| NM_009237        | SRY-box containing gene 3 | Sox3        | 1.37        | 0.14    |
| NM_011486        | Signal transducer and activator of transcription 3 | Stat3       | 1.18        | 0.10    |
| NM_011577        | Transforming growth factor, beta 1 | Tgfb1       | 1.36        | 0.0003  |
| NM_009377        | Tyrosine hydroxylase | Th          | 1.61        | 0.27    |
| NM_022312        | Tenascin R | Tnr         | 1.40        | 0.001   |
| NM_009505        | Vascular endothelial growth factor A | Vegfa       | 1.47        | 0.01    |
Ascn1, Atpb1, Bmp4, Pax6, Ptnt, Robo1.

Bdnf, Creb1, Egf, Mtap2, Mill1, Nf1, Tnr, Tgfb1, Vegfa.

Ache, Cdk5rap2, Cdk5r1, Dcx, Grin1, H3d4, H3p4, Ndp, Pou3f3,

Adora2a, App, Dlg4, Mef2c, Neurod1, Nrcam.

Fina, Heyl, Mdk, Nrp2, Ntf3, Nog.

Figure 6. One month of brief, daily exposure to enrichment alters gene expression in both arsenic-exposed and control animals. A Venn diagram depicts gene expression alterations after brief, daily exposure to enrichment for one month in control animals (right) and in arsenic-exposed animals (left). Fold changes of displayed genes include up and down regulation, p<.05 (Tables 2, 3). Gene expression changes common to both sets of animals are displayed in the middle. These include genes involved in cell signaling, axonal growth, histone maintenance, receptors, and cell cycle dynamics.
doi:10.1371/journal.pone.0073720.g006

Perinatal Arsenic Exposure Alters Neurogenesis

hyped in to increased apoptosis after developmental arsenic exposure, a study demonstrated significant downregulation of nerve growth factor (NGF) and GAP-43 mRNA [51] in response to arsenic, similar to the results from our arrays showing significant downregulation of mRNA from Ptn, Odz1, and Fg2. These growth factors are also involved in axonogenesis and neurite outgrowth, which arsenic exposure can impair [52]. Similarly, several important genes responsible for proper maturation and axonal growth including doublecortin, tenascin R, Mtap2, and Robo1 are all significantly downregulated in arsenic-exposed animals (Table 1). This further supports the notion that arsenic is impacting the ability of NPC to develop into mature neurons, possibly leading to the decrease in differentiated neurons in the dentate gyrus. It should be noted that the number of surviving neural progenitors does affect the number of differentiated cells as well; however, NPC survival was not assessed after four weeks. Thus, it is unclear whether this lack of differentiated cells is due to deficits in the surviving NPC population or issues with differentiation program; however, the gene expression data do suggest that arsenic exposure is impacting neurogenesis programs in the dentate gyrus.

Several pathways, including Notch, TGFβ, and WNT, all had factors that were aberrantly expressed in the arsenic-exposed animals (Table 1). Interestingly, arsenic induced an upregulation of DIl1, a ligand that promotes Notch signaling, which enhances proliferation of progenitor cells. However, increased DIl1 also drives the downregulation of Ascl1, which was also downregulated in arsenic-exposed animals. Ascl1, or Mash1, is a basic helix-loop-helix (bHLH) transcription factor that increases expression of neurogenins to promote neuronal differentiation programs [53]. Thus, the Notch signaling program may be enhanced at the expense of the differentiation of progenitors as reflected in the deficits in differentiation of NPCs in arsenic-exposed animals [54]. Arsenic exposure resulted in downregulation of other factors important for differentiation including Odz and Nrg1 (also involved in Notch signaling) and a trend toward downregulation of neurogenins 1 and 2, though not significant. Thus, all of these changes in genes important for proper differentiation could be contributing to the lack of differentiated cells we observed after developmental arsenic exposure.

It’s well established that exposure to an enriched environment can lead to increased adult neurogenesis, thereby enhancing certain forms of learning and memory [29,32]. Yet, our previous publications have demonstrated that developmental toxins, such as alcohol, reduce the ability of the neurogenic environment in the hippocampus to respond to a continuous enrichment paradigm [55]. Other studies reveal that brief exposure to enrichment is adequate to improve behavior and adult neurogenesis [56–58]. To reduce the likelihood that animals habituate to the enriched housing environment, we decided to use a “playground” enrichment paradigm in which animals spend two to four hours per day in the enrichment cages (with toys, ladders, running wheels, housing, and other animals) and are subsequently returned to their standard home cages. We found that this model of brief, daily exposure to enrichment sufficiently increased both proliferation and differentiation in both control and arsenic-exposed animals regardless of perinatal exposure. The effect on control animals was as expected: significantly increased proliferation of 70%, likely due to exercise from use of the running wheel as suggested by work from van Praag, and significantly increased differentiation of 39%, likely due to exposure to novelty, other animals, and toys [59]. The use of both a running wheel and toys for enrichment has additive effects on adult neurogenesis and may likely account for the robust increase seen in both sets of animals [34]. While the increase in proliferation of arsenic-exposed animals after enrichment was not significant, we consider a 53% increase to be considerable. Qualitative evidence suggests that a substantial difference exists even if not statistically significant (Figure 4C). Two reasons for this lack of significance include 1) the inherent variability in measuring neurogenesis and 2) the fact that, while arsenic may influence NPC proliferation, this impact may only be observed as the lack of significant neurogenic response to the enrichment, as seen in other studies using teratogens (e.g., alcohol) [55]. Surprisingly, we found that brief exposure to...
observed in our arsenic model. We have demonstrated that exposure to 50 ppb arsenic, which is metabolized more efficiently in the mouse and models a 10 ppb arsenic exposure in humans, during all three trimesters of gestational and postnatal development induces hippocampal-dependent learning and memory deficits [6,13]. Results presented here indicate it is likely that altered neurogenesis is one mechanism responsible for these deficits. This study is the first to show that developmental exposure to a low concentration of arsenic induces changes in the number of differentiated adult neural progenitors in the subgranular zone of the hippocampus and aberrant expression of neurogenesis-related genes. Further studies are needed to elucidate mechanisms that produce these genetic and morphological changes we have observed.

Acknowledgments
The authors would like to thank Samantha Goggin and Matthew Labrecque for technical assistance.

Author Contributions
Conceived and designed the experiments: CRT AMA. Performed the experiments: CRT. Analyzed the data: CRT. Contributed reagents/materials/analysis tools: AMA. Wrote the paper: CRT.

References
1. Brinkl J, Khan MH, Kraemer A (2009) A systematic review of arsenic exposure and its social and mental health effects with special reference to Bangladesh. Int J Environ Res Public Health 6: 1609–1619.
2. Calderon J, Navarro ME, Jimenez-Capdeville ME, Santos-Diaz MA, Golden A, et al. (2001) Exposure to arsenic and lead and neuropsychological development in Mexican children. Environ Res 85: 69–76.
3. Nagaraja TN, Desiraju T (1994) Effects on operant learning and brain acetylcholine esterase activity in rats following chronic inorganic arsenic intake. Hum Exp Toxicol 13: 353–356.
4. Chattopadhyay S, Bhaumik N, Nag Chaudhury A, Das Gupta S (2002) Arsenic induced changes in growth development and apoptosis in neonatal and adult brain cells in vivo and in tissue culture. Toxicol Lett 128: 73–84.
5. Rodrigues VM, Carrazales L, Mendoza MS, Fajardo OR, Gieraltowski M (2002) Effects of sodium arsenate exposure on development and behavior in the rat. Neurotoxicol Teratol 24: 743–750.
6. von Ehrenstein OS, Poddar S, Yuan Y, Mazumder DG, Eskenazi B, et al. (2007) Neurotoxicological studies of sodium arsenite exposure on development and behavior in the rat. Neurotoxicol Teratol 29: 475–484.
7. Wasserman GA, Liu X, Parvez F, Ahsan H, Factor-Litvak P, et al. (2007) Water arsenic exposure and intellectual function in 6-year-old children in Araihazar, Bangladesh. Environ Health Perspect 115: 285–289.
8. Martinez-Finley EJ, Ali AM, Allan AM (2009) Learning deficits in C57BL/6J mice following perinatal arsenic exposure: consequence of lower corticosterone receptor levels? Pharmacol Biochem Behav 94: 271–277.
9. O’Byrant SE, Edwards M, Menson CV, Gong G, Barber R (2011) Long-term low-level arsenic exposure is associated with poorer neuropsychological functioning: a Project FRONTIER study. Int J Environ Res Public Health 8: 861–874.
10. Dhar P, Mohani N, Mehra RD (2007) Preliminary morphological and morphometric study of rat cerebellum following sodium arsenite exposure during rapid brain growth (RBG) period. Toxicology 234: 10–20.
11. Siddhu JS, Ponce RA, Vredevoogd MA, Yu X, Grabbe E, et al. (2006) Cell cycle inhibition by sodium arsenite in primary embryonic rat midbrain neourethelial cells. Toxicol Sci 89: 475–484.
12. Goggin S, Labrecque MT, Allan AM (2012) Perinatal exposure to 50 ppb sodium arsenite induces hypothalamic-pituitary-adrenal axis dysregulation in male C57BL/6 mice. Neurotoxicology 33: 1338–1345.
13. Martinez EJ, Kolb BI, Bell A, Savage DD, Allan AM (2008) Moderate perinatal arsenic exposure alters neuroendocrine markers associated with depression and increases depressive-like behaviors in adult mouse offspring. Neurotoxicology 29: 647–655.
14. Shors TJ, Townend DA, Zhao M, Kozorovitsky Y, Gould E (2002) Neurogenesis may relate to some but not all types of hippocampal-dependent learning. Hippocampus 12: 350–384.
15. Sahay A, Sobiche KN, Hill AS, O’Carroll CM, Kharkurin MA, et al. (2011) Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature 472: 466–470.
16. Dong W, Aimone JB, Gage FH (2010) New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 11: 339–350.
17. Shors TJ, Anderson ML, Cufick DM 2nd, Niska MS (2012) Use it or lose it: how neurogenesis keeps the brain fit for learning. Behav Brain Res 227: 450–458.
18. Jesberger S, Clark RK, Broadbent NJ, Clemenson GD Jr, Consoligo A, et al. (2009) Dentine gyrus-specific knockdown of adult neurogenesis impairs spatial and object recognition memory in adult rats. Learn Mem 16: 147–154.
19. Nixon K, Crewe FT (2005) Binge ethanol exposure decreases neurogenesis in adult rat hippocampus. J Neurochem 83: 1087–1093.
20. Knitslov AJ, Helfer JL, Calizo LH, Dong WK, Goodlett CR, et al. (2007) Persistent impairment of hippocampal neurogenesis in young adult rats following early postnatal alcohol exposure. Alcohol Clin Exp Res 31: 2073–2082.
21. Gil-Mohapel J, Boehme F, Patten A, Cox A, Kaiser L, et al. (2011) Altered adult hippocampal neuronal maturation in a rat model of fetal alcohol syndrome. Brain Res 1384: 29–41.
22. Valdivos DN, Adriani W, Montarou MF, Auroseuce C, Rougon G, et al. (2002) Nicotine self-administration impairs hippocampal plasticity. J Neurosci 22: 3656–3666.
23. Shingo AS, Kato S (2005) Effects of nicotine on neurogenesis and plasticity of hippocampal neurons. J Neural Transm 112: 1473–1478.
24. Jakovac-Movic K, Zarkovski TV, Romantchik OJ, Jurgenson M, Mirsefah E, et al. (2005) Developmental lead exposure impairs contextual fear conditioning and reduces adult hippocampal neurogenesis in the rat brain. Int J Dev Neurosci 23: 627–635.
25. Verina T, Rohde CA, Guilarte TR (2007) Environmental lead exposure during early life alters granule cell neurogenesis and morphology in the hippocampus of young adult rats. Neuroscience 145: 1037–1047.
26. Gilbert ME, Kelly ME, Samsam TE, Goodman JH (2005) Chronic developmental lead exposure reduces neurogenesis in adult rat hippocampus but does not impair spatial learning. Toxicol Sci 86: 365–374.
27. Falnul-Morel A, Sokolowski K, Sutti HM, Zhou X, Shors TJ, et al. (2007) Developmental mercury exposure elicits acute hippocampal cell death, reductions in neurogenesis, and severe learning deficits during puberty. J Neurochem 103: 1968–1981.
28. Faustman EM, Ponce RA, Ou YC, Mendoza MA, Lewandowski T, et al. (2002) Investigations of methylmercury-induced alterations in neurogenesis. Environ Health Perspect 110 Suppl 5: 859–864.
29. Kempermann G, Kuhn HG, Gage FH (1997) More hippocampal neurons in adult mice living in an enriched environment. Nature 386: 493–495.
30. van Praag H, Christie BR, Sejnowski TJ, Gage FH (1999) Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci U S A 96: 13427–13431.
31. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104–9110.
32. Zhao C, Deng W, Gage FH (2008) Mechanisms and functional implications of adult neurogenesis. Cell 132: 645–660.

PLOS ONE | www.plosone.org 18 September 2013 | Volume 8 | Issue 9 | e73720
33. Koh S, Magid R, Chung H, Stine CD, Wilson DN (2007) Depressive behavior and selective down-regulation of serotonin receptor expression after early-life seizures: reversal by environmental enrichment. Epilepsy Behav 10: 26–31.

34. Fabel K, Wolf SA, Ehniger D, Babu H, Leal-Gadria P, et al. (2009) Additive effects of physical exercise and environmental enrichment on adult hippocampal neurogenesis in mice. Front Neurosci 3: 50.

35. Hayes NL, Nowakowski RS (2002) Dynamics of cell proliferation in the adult dentate gyrus of two inbred strains of mice. Brain Res Dev Brain Res 134: 77–85.

36. Guo W, Zhang L, Christopher DM, Teng ZQ, Fausett SR, et al. (2011) RNA-binding protein FXR2 regulates adult hippocampal neurogenesis by reducing Noggin expression. Neuron 70: 924–938.

37. Piao F, Ma N, Hiraku Y, Murata M, Oikawa S, et al. (2005) Oxidative DNA damage in relation to neurotoxicity in the brain of mice exposed to arsenic at environmentally relevant levels. J Occup Health 47: 443–449.

38. Brady ML, Diaz MR, Inso A, Everett JC, Valenzuela CF, et al. (2013) Moderate prenatal alcohol exposure reduces plasticity and alters NMDA receptor subunit composition in the dentate gyrus. J Neurosci 33: 1062–1067.

39. Hagihara H, Toyama K, Yamasaki N, Miyakawa T (2009) Dissection of hippocampal dentate gyrus from adult mouse. J Vis Exp.

40. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.

41. Hong GM, Bain LJ (2012) Arsenic exposure inhibits myogenesis and neurogenesis in P19 stem cells through repression of the beta-catenin signaling pathway. Toxicol Sci 129: 146–156.

42. Luo JH, Qiu ZQ, Zhang L, Shu WQ (2012) Arsenite exposure altered the expression of NMDA receptor and postsynaptic signaling proteins in rat hippocampus. Toxicol Lett 211: 39–44.

43. Martinez-Finley EJ, Goggin SL, Labrecque MT, Allan AM (2011) Reduced expression of MAPK/ERK genes in perinatal arsenic-exposed offspring induced by glucocorticoid receptor deficits. Neurotoxicol Teratol 33: 530–537.

44. Liu S, Piao F, Sun X, Bai L, Peng Y, et al. (2012) Arsenic-induced inhibition of hippocampal neurogenesis and its reversibility. Neurotoxicology 33: 1033–1039.

45. Martinez L, Jimenez V, Garcia-Sepulveda C, Ceballos F, Delgado JM, et al. (2011) Impact of early developmental arsenic exposure on promoter CpG-island methylation of genes involved in neuronal plasticity. Neurochem Int 58: 574–581.

46. Reichard JF, Paga A (2010) Effects of arsenic exposure on DNA methylation and epigenetic gene regulation. Epigenomics 2: 87–104.

47. Xie J, Jiang H, Wan YH, Du AY, Guo KJ, et al. (2011) Induction of a 55 kDa acetylcholinesterase protein during apoptosis and its negative regulation by the Akt pathway. J Mol Cell Biol 3: 250–259.

48. Yadav RS, Chandravanshi LP, Shukla RK, Sankhwar ML, Ansari RW, et al. (2011) Neuroprotective efficacy of curcumin in arsenic induced cholinergic dysfunctions in rats. Neurotox Res 32: 760–768.

49. Veena J, Rao BS, Srikumar BN (2011) Regulation of adult neurogenesis in the hippocampus by stress, acetylcholine and dopamine. J Nat Sci Biol Med 2: 26–37.

50. Ghosal K, Stathopoulos A, Pimplikar SW (2010) APP intracellular domain impacts adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One 5: e11866.

51. Fan MQ, Zhi-QZ, Peng Z (2013) [Effects of arsenic on nerve growth factor and nerve growth related mRNA expression in F1 hippocampal]. Sichuan Da Xue Xue Bao Yi Xue Ban 44: 53–56.

52. Aung KH, Kurihara R, Nakashima S, Maekawa F, Nohara K, et al. (2013) Inhibition of neurite outgrowth and alteration of cytoskeletal gene expression by sodium arsenite. Neurotoxicology 34: 226–235.

53. Ables JL, Breunig JJ, Eisch AJ, Rakic P (2011) Not(ch) just development: Notch signalling in the adult brain. Nat Rev Neurosci 12: 269–283.

54. Shimozu H, Ohtsuka T, Kaizyama R (2011) Dynamic expression of notch signaling genes in neural stem/progenitor cells. Front Neurosci 5: 78.

55. Choi IV, Allan AM, Cunningham LA (2003) Moderate fetal alcohol exposure impairs the neurogenic response to an enriched environment in adult mice. Alcohol Clin Exp Res 29: 2053–2062.

56. Rampon C, Tang YP, Goodhouse J, Shimizu E, Kyin M, et al. (2000) Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat Neurosci 3: 238–244.

57. Frick KM, Fernandez SM (2003) Enrichment enhances spatial memory and increases synaptophysin levels in aged female mice. Neurobiol Aging 24: 615–620.

58. Veena J, Srikumar BN, Mahatii K, Bhagya V, Raju TR, et al. (2009) Enriched environment restores hippocampal cell proliferation and ameliorates cognitive deficits in chronically stressed rats. J Neurosci Res 87: 831–843.

59. van Praag H (2008) Neurogenesis and exercise: past and future directions. Neuronomolecular Med 10: 128–140.